Maexeni (Ethinylestradiol, Levonorgestrel)

Maexeni, a combined oral contraceptive, is indicated for hormonal contraception to prevent pregnancy.

• Contraception: prevents pregnancy by suppressing ovulation and modifying cervical mucus.
• Family planning: provides reliable birth control for women of reproductive age.
• Menstrual cycle regulation: helps achieve more predictable bleeding patterns and reduces menstrual discomfort.

• Ethinylestradiol and levonorgestrel bind to estrogen and progesterone receptors, respectively, suppressing the hypothalamic‑pituitary‑gonadal axis. This reduces the secretion of follicle‑stimulating hormone (FSH) and luteinising hormone (LH), preventing follicular development and ovulation. The progestin component also thickens cervical mucus and induces endometrial changes that are unfavorable for implantation.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Breast tenderness: temporary swelling or discomfort.
• Headache: occasional tension‑type headaches.
• Spotting or breakthrough bleeding: irregular light bleeding.
• Mood changes: irritability or mild mood swings.
• Weight fluctuation: slight increase or fluid retention.

Serious or Rare Side Effects

• Deep vein thrombosis: blood clot formation in veins.
• Pulmonary embolism: clot migration to lung vessels.
• Stroke: cerebrovascular accident due to clot or hemorrhage.
• Myocardial infarction: heart attack risk, especially in smokers.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Liver tumor: rare hepatic adenoma development.

Before initiating Maexeni, consider the following precautions.

• Cardiovascular assessment: evaluate risk factors such as hypertension, smoking, or clotting disorders.
• Liver function: avoid use in patients with active liver disease or severe hepatic impairment.
• Smoking status: advise women over 35 who smoke to discontinue use.
• Missed dose management: provide clear instructions for handling forgotten tablets.
• Concomitant medications: review other drugs that may affect efficacy or safety.
• Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Maexeni may interact with several medicines that alter its effectiveness or safety.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): markedly reduce contraceptive efficacy.
• St. John’s wort: may decrease hormone levels, leading to breakthrough bleeding.
• Certain antiepileptics (e.g., phenobarbital): lower plasma concentrations of the active ingredients.

Moderate Interactions (Monitor Closely)

• Antifungals (e.g., ketoconazole, itraconazole): may increase hormone levels, raising side‑effect risk.
• HIV protease inhibitors (e.g., ritonavir): can elevate plasma concentrations.
• Selective serotonin reuptake inhibitors (e.g., fluoxetine): may modestly affect hormone metabolism.
• Diuretics and antihypertensives: monitor blood pressure as hormonal changes can influence fluid balance.